Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
about
Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis CParitaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise reviewType 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the SpotlightA Single-Cell Platform for Monitoring Viral Proteolytic Cleavage in Different Cellular CompartmentsSofosbuvir/velpatasvir: A promising combinationReconstitution and Functional Analysis of a Full-Length Hepatitis C Virus NS5B Polymerase on a Supported Lipid Bilayer.Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphomaHepatitis B virus infection and alcohol consumptionComprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir.Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems.Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve PatientsScreening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia.Trends in the Mortality of Hepatocellular Carcinoma in the United States.Emerging biological agents for hepatitis C.Hepatitis C virus resistance to the new direct-acting antivirals.Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.Antiviral therapies for managing viral hepatitis in lymphoma patients.Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015).Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4.Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.Efficacy and Safety of Glecaprevir/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection.Sofosbuvir/Velpatasvir in Patients With Hepatitis C Virus Genotypes 1-6 and Compensated Cirrhosis or Advanced Fibrosis.Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants.In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation.Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index.Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES.How I treat hepatitis C virus infection in patients with hematologic malignancies.Resistance Characterization of Ledipasvir and Velpatasvir in Hepatitis C Virus Genotype 4.Hepatitis C in a new therapeutic era: Recontextualising the lived experience.Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results.Hepatitis C Virus Clearance in Older Adults.Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil.Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
P2860
Q26741123-039AEC3C-B13D-46F7-BFBD-81F683BD1EA2Q26747705-83452499-2BCF-4471-923D-D4715F3C0ACCQ26752583-525A4A3C-A262-4114-8577-011B5840F7F8Q27468663-19A909DA-83E6-49D5-9666-E8CF38E6F974Q27468954-52E1D67F-1721-48A1-8B62-C08F12753750Q27469069-8591D159-55F5-4611-8461-4A5C7EA4095DQ28080160-8BCA995F-8AA6-424A-B6CD-4751057091ACQ33599503-059C7130-9C8A-4000-86CF-575EF863EB35Q35917596-C863D6AE-D83C-4502-A5AB-EB2CC1794A1FQ36166222-9E11FA31-E15D-4860-ABF3-7332023AE003Q37148014-0713CBEA-E544-4888-9245-0FD5B0FADF4FQ37286311-47DB3444-2ACD-4693-8C62-A48D77BF05FFQ37454038-9E1E125A-4000-4443-8418-BC9478B7C18CQ38635553-FC78B52E-05BF-443A-BFE9-9E087222D143Q38820156-BE2F0272-83F2-4021-8E5D-A0CC6674C889Q38887954-8BCE0052-8129-4711-AAC9-DF391901B4BFQ38948533-3AD38163-ABD3-4F9A-95CD-43AD2356F023Q38978513-A9ED490F-6C6E-457B-A63E-CA5D27B34139Q38989625-3EEEB754-1516-4352-A7D4-411203804E91Q38992902-AB870C11-4085-40C4-B1A4-BBD5442F6F44Q39038238-474A84BF-EA2B-46CB-9C62-8934DC897F29Q39092977-6EE0B609-E0D1-4849-A3B3-3A8D0BE05E98Q39247347-EFB351AD-370F-46AB-8AE4-A24B948431D2Q39500905-517D8696-2BE4-4F9D-95DB-CA27045FDBC9Q40060636-62728B4D-061F-4062-8E65-ADF577718341Q40102621-4E899E96-C852-40AF-94CE-DEC1F43E2327Q40167650-096CA877-215A-46A5-B015-C67877956170Q40337619-FD2B63B0-39BC-40C4-9C26-9B4FDA1AC653Q40353248-EBC302D3-00B2-4B8A-8020-EDBEB3D09B02Q40356056-D150D8C1-250E-4C89-8CC0-CC514DA64DEDQ40400190-12CB282C-54E7-41E2-96B4-AC1E58CE1B05Q40469011-FBD0EA2B-2197-4F9A-B9EE-308BACD0C931Q40489570-78AD4775-8397-4DDC-B1DB-D157F8D3974DQ40604797-A57E90B4-6AC5-496C-A1CB-C38FC519513CQ41923068-206606A3-C810-4688-97DC-F2FA3185875BQ41928113-35972640-6ECC-4826-B7A0-D90D5143B360Q45324716-DBD7CDD2-6BF0-4ED3-9212-5D727617AD7AQ45324869-89F51651-81C4-4D82-8B1E-AD2F1CE9C4E0Q45324912-2EC1DFB5-13A5-45BB-94A2-1BCFC6ECB0A7Q45325188-2A2C2419-FAF8-4CB6-8C87-9C16E70CC6B9
P2860
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Direct-acting antivirals for t ...... tment and future perspectives.
@ast
Direct-acting antivirals for t ...... tment and future perspectives.
@en
Direct-acting antivirals for t ...... tment and future perspectives.
@nl
type
label
Direct-acting antivirals for t ...... tment and future perspectives.
@ast
Direct-acting antivirals for t ...... tment and future perspectives.
@en
Direct-acting antivirals for t ...... tment and future perspectives.
@nl
prefLabel
Direct-acting antivirals for t ...... tment and future perspectives.
@ast
Direct-acting antivirals for t ...... tment and future perspectives.
@en
Direct-acting antivirals for t ...... tment and future perspectives.
@nl
P2093
P2860
P356
P1433
P1476
Direct-acting antivirals for t ...... tment and future perspectives.
@en
P2093
Michele Martinot-Peignoux
Nathalie Boyer
Patrick Marcellin
Tarik Asselah
P2860
P356
10.1111/LIV.13027
P478
36 Suppl 1
P577
2016-01-01T00:00:00Z